Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

UnitedHealth Group Names Andrew Witty as President

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/11/2019 | 08:35am EST

By Colin Kellaher

UnitedHealth Group on Monday said it named Andrew Witty as president.

The Minnetonka, Minn., health insurer said Mr. Witty has been executive vice president of UnitedHealth and chief executive of its Optum unit since in March 2018.

UnitedHealth said Mr. Witty, who will retain his duties as Optum chief executive, will also oversee enterprise business strategy formulation; enterprise business development and partnerships; and enterprise research and development and clinical capacities.

Mr. Witty, who is currently a member of UnitedHealth's office of the chief executive, was chief executive of GlaxoSmithKline PLC from 2008 to 2017.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN -0.19% 220.7 Delayed Quote.13.37%
GLAXOSMITHKLINE 0.31% 1725 Delayed Quote.15.22%
UNITEDHEALTH GROUP -1.12% 254.09 Delayed Quote.3.15%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
11/11ANDREW WITTY : UnitedHealth Group Names Andrew Witty as President
DJ
11/07GLAXOSMITHKLINE : EACS 2019 ViiV Healthcare to present 17 abstracts from its por..
AQ
10/31UK's winter election - What's in it for markets?
RE
10/30LONDON STOCK EXCHANGE : Pharma stocks lift FTSE 100 out of red
RE
10/30GLOBAL MARKETS LIVE : PSA, Fiat Chrysler, Macquarie, WhatsApp…
10/30GSK raises profit forecast after shingles vaccine sales boost
RE
10/30GLAXOSMITHKLINE : Intravenous Benlysta is the first biologic treatment to be app..
AQ
10/30GlaxoSmithKline Raises Guidance After 3Q Profit Rise -- Update
DJ
10/30GLAXOSMITHKLINE : 3rd Quarter Results
PU
10/30GLAXOSMITHKLINE : Raises Outlook as 3Q Revenue, Profit Grow
DJ
More news
Financials (GBP)
Sales 2019 33 573 M
EBIT 2019 8 976 M
Net income 2019 4 388 M
Debt 2019 25 288 M
Yield 2019 4,64%
P/E ratio 2019 18,9x
P/E ratio 2020 15,8x
EV / Sales2019 3,29x
EV / Sales2020 3,06x
Capitalization 85 233 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 1 803,68  GBp
Last Close Price 1 722,20  GBp
Spread / Highest target 27,7%
Spread / Average Target 4,73%
Spread / Lowest Target -12,3%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE15.22%109 685
JOHNSON & JOHNSON3.06%344 670
ROCHE HOLDING AG22.19%254 722
MERCK AND COMPANY8.99%211 953
PFIZER-15.40%208 023
NOVARTIS17.78%198 320